BIOMOTION PHARMA ApS: Financial statements 2023
CVR: 12928203
Source: annual report 2023, Danish Business Authority
01/10/2022 – 30/09/2023
BIOMOTION PHARMA ApS (CVR 12928203) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -1,430 and a net result of DKK -1,430 compared with DKK 6,200 the year before. Equity in the 2023 report amounted to DKK 9,770. The solvency ratio was 88.7%.
- Revenue
- DKK 0
- Gross Profit
- DKK -1,430
- Profit/Loss
- DKK -1,430
- Equity
- DKK 9,770
- Total Assets
- DKK 11,020
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | 0 | -1 t. | -1 t. | 10 t. | - |
| 2022 | 16 t. | 6 t. | 6 t. | 11 t. | - |
| 2021 | - | -1 t. | 4 t. | 5 t. | - |
| 2020 | - | -1 t. | -1 t. | 1 t. | - |
| 2019 | - | -2 t. | -2 t. | 3 t. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
BIOMOTION PHARMA ApS has published its annual report for 2022. Revenue came to DKK 16,000, and the net result was DKK 6,200.
As of January 5, 2023, EY Godkendt Revisionspartnerselskab has stepped down as auditor of BIOMOTION PHARMA ApS.
About BIOMOTION PHARMA ApS
BIOMOTION PHARMA ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 1989. The company is in liquidation. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named HANDEL OG INVESTERING AF 1989 ApS and DANSK FARMASAN A/S. The management consists of Michael Rasmussen. The company is owned by Michael Rasmussen. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -4,000 and a net result of DKK -4,202 compared with DKK -6,460 the year before. Equity in the 2025 report amounted to DKK -892.